118th CONGRESS 1st Session |
To extend the National Alzheimer’s Project.
January 30, 2023
Mr. Tonko (for himself, Mr. Smith of New Jersey, and Ms. Waters) introduced the following bill; which was referred to the Committee on Energy and Commerce
To extend the National Alzheimer’s Project.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
This Act may be cited as the “NAPA Reauthorization Act”.
Section 2 of the National Alzheimer’s Project Act (42 U.S.C. 11225) is amended—
(A) in paragraph (2), by striking “and coordination of” and inserting “on, and coordination of,”;
(i) by redesignating subparagraphs (A) and (B) as subparagraphs (B) and (C), respectively; and
(ii) by inserting before subparagraph (B), as so redesignated, the following:
“(A) promotion of healthy aging and reduction of risk factors for Alzheimer’s;”;
(C) in paragraph (5), by striking “; and” and inserting a semicolon;
(D) by redesignating paragraph (6) as paragraph (7); and
(E) by inserting after paragraph (5) the following:
“(6) provide information on, and promote the adoption of, healthy behaviors that may reduce the risk of cognitive decline and promote and protect cognitive health; and”;
(A) by inserting “, across public and private sectors,” after “Nation’s progress”; and
(B) by inserting “, including consideration of public-private collaborations, as appropriate” before the period;
(i) in subparagraph (A), by adding at the end the following:
“(xi) A designee of the Department of Justice.
“(xii) A designee of the Federal Emergency Management Agency.
“(xiii) A designee of the Social Security Administration.
“(xiv) A designee of the Office of Management and Budget.
“(xv) 1 or more other designees of the Department of Health and Human Services, as determined by the Secretary of Health and Human Services.”; and
(I) in the matter preceding clause (i), by striking “12” and inserting “14”;
(aa) by striking “2 researchers” and inserting “3 researchers”; and
(bb) by striking “; and” and inserting “, including at least one researcher with demonstrated experience in recruitment and retention of diverse cohorts of clinical trial participants;”;
(III) in clause (vi), by striking the period and inserting “; and”; and
(IV) by adding at the end the following:
“(vii) an individual with a diagnosis of Alzheimer’s disease.”;
(I) by striking “an initial evaluation” and inserting “annual evaluations”; and
(II) by striking “research, clinical” and inserting “research, risk reduction, public health, clinical”;
(ii) in subparagraph (B), by striking “initial”;
(I) in the matter preceding clause (i), by striking “initial”; and
(II) in clause (ii), by inserting “and reduce disparities” before the semicolon; and
(iv) in subparagraph (D), by striking “annually thereafter, an evaluation” and inserting “annual evaluations”; and
(C) in paragraph (6), by striking “2025” and inserting “2035”;
(4) in subsection (g)(3)(A)(ii), by inserting “and reduce disparities” before the semicolon; and
(5) in subsection (h), by striking “2025” and inserting “2035”.